Stealth BioTherapeutics (MITO) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices sink, shrugging off renewed Middle East fighting
- ASML capacity upgrade soothes AI chip bottleneck fears
Stealth BioTherapeutics Reports First Quarter 2021 Financial Results And Recent Business Highlights
May 18, 2021 7:30 AM EDTBOSTON, May 18, 2021 /PRNewswire/ --Â Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the quarter ended March 31, 2021 and announced recent business highlights.
